This narrow-moat pharma firm's focus on acquiring already-approved products that aren't subject to reimbursement pressure is misunderstood.
Declining fuel prices stoked great returns at several of these companies, but that's not a lasting advantage.
Still gas in the tank for Apple, Facebook gets mobile mojo, a possible wide-moat combination, and more.
Those with a long-term focus will earn attractive returns as the true earnings power of this firm's growth-driving product becomes apparent during the next three years.
Recent deals have been driven more by tax strategies than therapeutic synergies.
While more than one third of these top fund managers are outperforming this year, four of them stand out from the rest given their ability to outperform the market over almost all time periods.
The pickings continue to get slimmer for a proven group of top fund managers as the market continues to trade around its all-time high.
This screen looks for good buys in a hot part of the market.
Use this screen to find companies that have produced strong growth despite the recession.
Four offerings deemed to be right for right now.